By Ashish Jain
Small and mid-size biopharma companies in the U.S. and Europe are under intense pressure to find more efficient and cost-effective ways to commercialize their products. In an increasingly competitive clinical trial environment, sponsors have begun to shift their focus to the Asia-Pacific (APAC) region for their studies. In fact, the number of clinical trials in the U.S. has been on a gradual decline since 2014, while Asia has seen a steady increase.
Here are five reasons why the APAC region may be a good fit for your global clinical trial.